Centene Corporation
HealthcareNYSE:CNC · New York Stock Exchange
+$2.06 today
Vol 2.82M · Avg 6.36M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-33.4%
avg 5.8%
ROIC
-13.4%
avg 3.3%
ROA
-8.6%
avg 2.0%
Analysis
ROA is currently the strongest return metric at -8.6% versus its period average of 2.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Sarah London | Chief Executive Officer & Director | $3.97M | — | 45 | $1.19M | 0.24% |
Andrew Lynn Asher | Executive Vice President & Chief Financial Officer | $2.71M | — | 57 | $747,989.48 | 0.15% |
Christopher Andrew Koster | Executive Vice President, General Counsel & Secretary | $1.40M | — | 61 | $18,148.93 | <0.01% |
Susan Smith | Chief Operating Officer | $1.31M | — | 50 | $212,720.00 | 0.04% |
Tanya McNally | Senior Vice President & Chief People Officer | $1.20M | — | 52 | $127,258.00 | 0.03% |
Brian Phillip LeClaire | Chief Information Officer | — | — | 66 | — | — |
Theodore Pienkos | Corporate Controller & Chief Accounting Officer | — | — | 44 | $24,747.98 | <0.01% |
Ashlee Knuckey | Chief Risk, Ethics & Compliance Officer | — | — | — | — | — |
Cary D. Hobbs | Executive Vice President & Chief of Staff | — | — | 58 | — | — |
Jennifer Lynch Gilligan | Senior Vice President of Investor Relations | — | — | — | — | — |
Reverend Patrick J. Frawley | Senior Vice President of Social Responsibility | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$738,945.00
Sells
3
$7.74M
Net Sentiment
$7.00M
Net selling
Most Active
Burdick Kenneth A
3 transactions
Analysis
Insiders reported 2 buys worth $738,945.00 and 3 sells worth $7.74M over the last 12 months. That adds up to net selling of $7.00M. Burdick Kenneth A was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +476.9% | +13.2% (15yr)1 analysts |
| Revenue | N/A | N/A | +41.1% | +16.1% (15yr)5 analysts |
| Net Income | N/A | N/A | +462.0% | +18.5% (15yr)5 analysts |
| EBIT | N/A | N/A | +86.9% | +9.4% (15yr)5 analysts |
Analysis
Recent growth has been strongest in EPS at +476.9% over three years. Forward estimates point to Net Income at +18.5% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Illumina, Inc.
NASDAQ:ILMN
$24.35B
Royalty Pharma plc
NASDAQ:RPRX
$23.71B
Hologic, Inc.
HOLX
$16.97B
Genmab A/S
NASDAQ:GMAB
$15.35B
Tenet Healthcare Corporation
NYSE:THC
$15.29B
Medpace Holdings, Inc.
NASDAQ:MEDP
$13.40B
Smith & Nephew plc
NYSE:SNN
$12.96B
Fresenius Medical Care AG & Co. KGaA
NYSE:FMS
$12.35B
Universal Health Services, Inc.
NYSE:UHS
$9.22B
Tempus AI, Inc.
NASDAQ:TEM
$8.30B
Who manages CNC?
Centene Corporation (CNC) lists 11 active executives. The top listed executive is Andrew Lynn Asher, Executive Vice President & Chief Financial Officer.
Are CNC insiders buying or selling?
Recent insider activity shows net selling of $31.85M.
Explore More
Continue the stock analysis
Jump to another research area for this company.